Ad blocking detected

Thank you for visiting CanadianInsider.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). Private browsing Firefox users should be able to disable tracking protection while visiting our website. Visit Mozilla support for more information. If you do not believe you have any ad-blocking software on your browser, you may want to try another browser, computer or internet service provider. Alternatively, you may consider the following if you want an ad-free experience.

Canadian Insider Club
$299/ year*
Daily Morning INK newsletter
+3 months archive
Canadian Market INK weekly newsletter
+3 months archive
30 publication downloads per month from the PDF store
Top 20 Gold, Top 30 Energy, Top 40 Stock downloads from the PDF store
All benefits of basic registration
No 3rd party display ads
JOIN THE CLUB

* Price is subject to applicable taxes.

Paid subscriptions and memberships are auto-renewing unless cancelled (easily done via the Account Settings Membership Status page after logging in). Once cancelled, a subscription or membership will terminate at the end of the current term.

iCo Therapeutics Inc. (V:ICO)

Business Focus: Biotechnology & Medical Research

Get the company report for the most recent outlook updated daily

Insider Chart - Past 6 Months

INK Ultra Money Free

Insider Filings

Latest 10 SEDI filings for ICO within the last 6 months
Loading...
See all filings within the past 6 months

Company News

Jun 22, 2020 19:33 ET
iCo Therapeutics Inc. Announces Oral Amphotericin B (iCo-019) Results to be Presented at Prestigious American Pharmaceutical Sciences Meeting and Discussion Updates
Vancouver, British Columbia--(Newsfile Corp. - June 22, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or the "Company") and its subsidiary, iCo Therapeutics Australia Pty Ltd., announced today that the American Association of Pharmaceutical Scientists ("AAPS") has accepted two presentations regarding iCo's Oral Amphotericin B technology (iCo-019) for the AAPS 2020 PharmSci 360 Meeting to be held October 26-November 5, 2020 (the "PharmSci 360 Meeting").
Read full article
May 29, 2020 18:00 ET
iCo Therapeutics Inc. Announces Q1 Interim Filing Update
Vancouver, British Columbia--(Newsfile Corp. - May 29, 2020) - iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) ("iCo" or "the Company") is providing an update on the status of the filing of its interim financial statements and accompanying management's discussion and analysis, and related CEO and CFO certifications for the three month period ended March 31, 2020 (collectively, the "Q1 Filings").
Read full article
See more news stories

Valuation Ratios

Industry
Sector
Beta
3.08
--
--
Price to Sales - TTM
--
10.96
8.60
Price to Book - most recent quarter
9.31
4.91
2.67
Price to Cash Flow per share - TTM
--
19.25
12.30
Price to Free Cash Flow per share - TTM
--
54.78
22.04
See all valuations

Short Report

DateNumber of Shares ShortedNet Change
Jun 30, 2020131,00035,468
Jun 15, 202095,532-28,468
May 31, 2020124,000-541,229
See Short Report

Business Summary

Sector:  Healthcare Industry:  Biotechnology & Medical Research

iCo Therapeutics Inc. (iCo) is a Canada-based biotechnology company principally focused on the identification, development and commercialization of drug candidates to treat sight-and life-threatening diseases. The Company principally focuses on in-licensing drug candidates with a clinical history, and re-dose, reformulate and develop drug candidates for the treatment of sight-and life-threatening diseases. The Company's product candidates include iCo-007, iCo-008 and an Oral AmpB Delivery System. The Company has initiated Phase II clinical trial for iCo-007. iCo-008 is a human monoclonal antibody that is offered to treat sight threatening forms of allergic conjunctivitis by neutralizing eotaxin-1, a ligand to the chemokine receptor CCR3. Oral AmpB Delivery System is a toxic option for the treatment of serious systemic fungal infections. The Company has completed pre-clinical studies for iCo's Oral AmpB Delivery System.

See business summary

 

Twitter

Search (past week) for $ICO.CA ICO.V